nicotine has been researched along with oxantel in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clark, CL; Martin, RJ; Robertson, AP; Trailovic, SM | 1 |
| Allegra, D; Bimonte, M; Gianni, D; Russo, T; Zambrano, N | 1 |
2 other study(ies) available for nicotine and oxantel
| Article | Year |
|---|---|
Oxantel is an N-type (methyridine and nicotine) agonist not an L-type (levamisole and pyrantel) agonist: classification of cholinergic anthelmintics in Ascaris.
Topics: Animals; Anthelmintics; Ascaris suum; Cluster Analysis; Dose-Response Relationship, Drug; Levamisole; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Pyrantel; Pyridines; Receptors, Cholinergic | 2004 |
Mutation of the feh-1 gene, the Caenorhabditis elegans orthologue of mammalian Fe65, decreases the expression of two acetylcholinesterase genes.
Topics: Acetylcholinesterase; Animals; Animals, Genetically Modified; Blotting, Southern; Caenorhabditis elegans Proteins; Carrier Proteins; Dose-Response Relationship, Drug; Gagging; Gene Expression Regulation; Intracellular Signaling Peptides and Proteins; Mammals; Membrane Proteins; Mutation; Nicotine; Nicotinic Agonists; Pyrantel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2004 |